Imeglimin: Finding a Place in Modern Diabetes Pharmacotherapeutics

Article Sidebar

PDF
Published: 2022-07-01
Keywords:
Gluconeogenesis, imeglimin, oxidative phosphorylation inhibitor, mitochondria, pharmacotherapeutics, type 2 diabetes mellitus

Main Article Content

Sanjay Kalra
Dept. of Endocrinology, Bharti Hospital, Karnal, Haryana, India; University Center for Research & Development, Chandigarh University, Mohali, Punjab, India
Saptarshi Bhattacharya
Dept. of Endocrinology, Apollo Indraprastha Hospital, New Delhi, India
Shehla Shaikh
Dept. of Endocrinology, Saifee Hospital, Mumbai, Maharashtra, India

Abstract

Type 2 diabetes mellitus (T2DM) is a multifactorial disease. Newer facets of its causation, clinical course, complications and therapy are being unraveled regularly. This editorial describes imeglimin, a first-of-class oxidative phosphorylation inhibitor, that has been approved for T2DM in Japan and India.

Article Details

Issue

Vol. 23 No. 3 (2022)

Section

Clinical Perspectives
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)

1 2 > >>